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Simple Summary: Treatment with anti-epidermal growth factor receptor (EGFR) monoclonal anti-
bodies (mAbs)—cetuximab and panitumumab—produced clinical benefits in a subset of patients
with metastatic colorectal cancer (mCRC). Here, the authors investigated the relative expression and
predictive value of HER family members in 144 patients with CRC. They found high levels of ex-
pression of HER2 in patients treated with cetuximab; these were associated with shorter progression
free survival (PFS). The results provide support for the emergence of HER2 as a therapeutic target in
patients with mCRC.
Abstract: The overexpressed HER2 is an important target for treatment with monoclonal antibody
(mAb) trastuzumab, only in patients with breast and gastric cancers, and is an emerging therapeutic
biomarker in metastatic colorectal cancer (mCRC) treated with anti-epidermal growth factor receptor
(EGFR) mAbs cetuximab and panitumumab. In this study, we investigated the relative expression
and predictive value of all human epidermal growth factor receptor (HER) family members in
144 cetuximab-treated patients with wild type RAS mCRC. The relative expression of EGFR and
HER2 have also been examined in 21-paired primary tumours and their metastatic sites by immuno-
histochemistry. Of the 144 cases examined, 25%, 97%, 79%, 48%, and 10% were positive for EGFR,
HER2, HER3, and HER4 and all four HER family members, respectively. The expression of EGFR
was an indicator of poorer overall survival and the membranous expression of HER2 and HER3 3+
intensity was associated with a shorter progression free survival (PFS). In contrast, the cytoplasmic
expression of HER2 was associated with better PFS. In 48% and 71% of the cases, there were dis-
cordance in the expression of EGFR or one or more HER family members in paired primary and
related metastatic tumours, respectively. Our results implicate the importance of a large prospective
investigation of the expression level and predictive value of not only the therapeutic target (i.e., EGFR
protein) but also HER2 and other HER family members as therapeutic targets, or for response to
therapy with anti-EGFR mAbs and other forms of HER inhibitors, in both the primary tumours and
metastatic sites in mCRC.
Keywords: metastatic colorectal cancer; HER2; cetuximab; predictive biomarker
1. Introduction
Colorectal cancer (CRC) is a heterogenous disease and one of the leading causes of
cancer deaths worldwide [1]. In the USA, it is predicted to be the third most commonly
diagnosed cancer (147,950) and the second leading cause of cancer deaths (53,200) [1,2].
Identification of cell surface antigens with high levels of expression in colorectal can-
cer resulted in the development and approval of several monoclonal antibody-based
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drugs for use in targeted therapy of metastatic colorectal cancer (mCRC) [3,4]. Currently,
anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (mAbs) cetuximab
and panitumumab, anti-vascular endothelial growth factor (VEGF) mAb bevacizumab,
and anti-VEGFR2 mAb ramucirumab are approved for the treatment of patients with
metastatic colorectal cancer [5–8]. Additionally, three checkpoint inhibitors namely anti-
PD-1 mAb nivolumab alone or in combination with anti-cytotoxic T-lymphocyte-associated
protein 4(CTLA-4) mAb ipilimumab and anti-programmed cell death protein 1 (PD-1) pem-
brolizumab have been approved for the treatment of patients with metastatic microsatellite
instability-high (MSI-H) or mismatch repair deficient (dMMR) colorectal cancer [9,10].
However, therapeutic benefits are seen in a subset of such patients and the duration of
response can also be short. Indeed, there is currently no reliable predictive biomarker for
the selection of patients who benefit from therapy with anti-EGFR antibodies [4]. In some
studies, tumour heterogeneity, mutations in RAS and the mAb binding sites have been
associated with resistance to anti-EGFR mAbs in patients with mCRC [11,12]. There is a
need for the identification of more reliable biomarkers for the response to therapy with
anti-EGFR antibodies in patients with mCRC [4,13].
EGFR (HER1/ErbB1) is a member of the type I growth factor receptor family of
tyrosine kinases (also known as ErbB/HER family), which consists of three other members
namely HER2 (neu, ErbB2), HER3 (ErbB3), and HER4 (ErbB4) [4]. EGFR is an important
therapeutic target for therapy with anti-EGFR antibodies, however, interestingly, the
expression of EGFR is not used for patient selection due to reports of response to cetuximab
in mCRC patients with EGFR negative tumours [14]. Indeed, while RAS mutation is
currently an important negative predictive biomarker for the response [15], not all patients
with a wild type KRAS and NRAS respond to, or gain benefit from therapy with anti-EGFR
mAbs. On the contrary, considerable objective responses have been reported in mCRC
patients with KRAS mutations treated with cetuximab [16–18]. More recently, other studies
have also reported emergence of KRAS mutations in liver metastases after anti-EGFR
treatment, highlighting the role of intra-tumour heterogeneity as a major contributing
factor for intrinsic and/or acquired resistance to anti-EGFR mAbs [19].
In light of the heterogenous nature of tumours and the high degree of crosstalk
between different receptor signalling pathways, in a limited number of studies, we and
others have reported the co-expression and prognostic significance of all members of the
HER family members and significant alterations were found in the expressions of HER1-4
in primary and corresponding metastatic lesions in patients with mCRC [20–23].
In the present study, we report for the first time the co-expression and predictive value
of all HER family members in 144 mCRC patients with RAS wild type, as well as changes in
such expression before and post cetuximab treatment, and their association with survival
and response to therapy.
2. Materials and Methods
In this retrospective study, 144 mCRC surgically resected and biopsy samples as well
as 21 paired metastatic specimens from patients between 2010 and 2018, treated with
FOLFOX (oxaliplatin and modified de Gramont) or FOLFIRI (irinotecan and modified de
Gramont) plus cetuximab were used. Before examination, ethical approval was obtained
via Research Ethics Committee (REC) of the Health Research Authority (HRA) (Integrated
Research Application System Project ID: 228447) and from the Research and Development
Committee of the Royal Surrey County Hospital. Response to cetuximab therapy was
evaluated using official reports, radiographic studies, including follow up computed
tomography scans and the Response evaluation criteria in solid tumors (RECIST) criteria
v1.1 [24]. For data analysis, response to cetuximab therapy was grouped as response
(full response or partial response) and no response (stable disease or disease progression),
clinical endpoints of death and recurrence were examined for overall survival (OS) and
progression free survival (PFS) to investigate the prognostic and predictive value of the
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biomarkers in line with the reporting recommendations for tumour marker prognostic
studies (REMARK) guidelines [25].
Tumour samples were routinely determined for RAS variants, prior to treatment
at Surrey Pathology Services, Royal Surrey County Hospital, Guildford (UK), using an
in-house developed panel of amplicons, which generates a library using the Thermo Fisher
Ion Chef. The library was then sequenced using the Thermo Fisher S5 platform and the Ion
Torrent server and the data analysed using the Thermo proprietary bioinformatics pipeline.
2.1. Immunohistochemistry
Immunohistochemical (IHC) staining was carried out using the Ventana Discovery
ULTRA IHC/ISH System (Roche, UK), as described previously [26]. The following primary
monoclonal antibodies, mouse anti-wild type EGFR (wtEGFR) specific, does not cross react
with the truncated EGFRvIII (M7298) 1:50, (Agilent, Stockport, UK), HER2 (3B5) 1:200,
(Insight Biotechnology, London, UK), HER3 (SP71) 1:50, (Abcam, Cambridge, UK), HER4
(HFR1) 1:100, (Insight Biotechnology, London, UK).
2.2. Scoring Criteria
The immunostaining of the tumour sections was scored as described previously [26].
Briefly, the HER immunostaining of the tumour sections was scored based on cut-off
values of >5%, >10%, >20%, and >50% of tumour cells, intensities of negative 0, weak 1+,
moderate 2+, and strong 3+ and localization of the HER immunostaining (i.e., membrane,
cytoplasm or nucleus of the cells). Scoring was conducted by two independent observers
(including a consultant histopathologist) who were blinded to all clinical information;
any disparity in scoring was resolved by simultaneous reassessment of the staining by
both observers.
2.3. Statistical Analysis
Statistical analysis was carried out in SPSS statistics 26 (SPSS Inc. Armonk, NY, USA)
and, where applicable, Fishers exact test, Kaplan–Meier survival plots, log rank-test, and
Cox survival regression models were used. All clinicopathological parameters (Table 1)
were initially considered for inclusion in Cox survival regression models. Additionally, OS
and PFS analysis were conducted by omitting the missing data. p ≤ 0.05 was considered
statistically significant.
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Table 1. Clinicopathological parameters and survival of 144 metastatic colorectal cancer (mCRC) patients treated with anti-epidermal growth factor receptor (EGFR) (mAb) cetuximab
or panitumumab. Progression free survival (PFS) and overall survival (OS) relative to the indicated features were determined by Kaplan–Meier analysis and the log-rank test.
p-Value of ≤0.05 was considered significant.
Characteristics Number of Patients (%) PFS in Months (Mean ± SE) 95% CI p-Value OS in Months (Mean ± SE) 95% CI p-Value
Age in years
NS NS≤70 85 (59) 53.7 ± 5.8 42.3–65.1 61.5 ± 4.6 52.5–70.6
>70 59 (41) 55.5 ± 5.6 44.4–66.5 67.6 ± 4.7 58.3–76.9
Gender
NS NSMale 101 (70) 47.1 ± 4.4 38.5–55.6 63.8 ± 3.2 57.4–70.1
Female 43 (30) 71.9 ± 7.0 58.1–85.6 59.4 ± 6.6 46.4–72.4
Tumour Type
NS NS
Resection 76 (53) 52.9 ± 6.0 41.2–64.6 63.2 ± 4.1 55.1–71.3
Liver Metastasis 11 (8) 39.14 ± 8.7 22.4–56.1 64.1 ± 5.5 53.3–74.9
Biopsy 57 (39) 48.4 ± 4.8 39.0–57.8 61.4 ± 6.5 48.5–74.2
T stage *
NS NS<T4 46 (32) 51.2 ± 6.9 37.5–64.9 63.8 ± 4.9 54.2–73.4
T4 33 (23) 38.8 ± 4.2 30.6–47.0 61.7 ± 6.6 48.9–74.6
N Stage *
NS NS<N2 41 (29) 50.5 ± 6.4 38.1–62.9 63.9 ± 4.3 55.6–72.3
N2 38 (26) 63.3 ± 7.8 48.0–78.5 65.1 ± 11.3 43.0–87.2
M Stage *
NS NSMx/M0 70 (49) 53.6 ± 6.1 41.5–65.6 64.7 ± 4.1 56.6–72.8
M1 11 (8) 25.8 ± 4.1 17.8–33.8 34.8 ± 3.0 28.9–40.7
Vascular Invasion *
NS NSV0 30 (21) 49.7 ± 7.6 34.8–64.7 63.6 ± 5.7 52.3–74.8
V1 49 (34) 54.7 ± 7.1 40.8–68.7 65.5 ± 5.9 53.9–77.0
LVI *
NS NSYes 39 (27) 55.5 ± 7.8 40.2–70.7 64.6 ± 4.9 54.8–74.4
No 39 (27) 50.1 ± 6.7 37.1–63.2 63.6 ± 6.4 51.1–76.1
Grade *
0.022 NSG1&G2 78 (54) 61.3 ± 6.1 49.4–73.1 63.0 ± 4.1 54.9–71.1
G3 32 (22) 31.9 ± 6.4 19.4–44.6 57.7 ± 6.2 45.4–69.9
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Table 1. Cont.
Characteristics Number of Patients (%) PFS in Months (Mean ± SE) 95% CI p-Value OS in Months (Mean ± SE) 95% CI p-Value
Apical Node *
NS NSNegative 67 (47) 53.4 ± 6.2 41.2–65.5 65.5 ± 4.1 56.4–72.7





cetuximab 25 (17) 45.8 ± 5.9 34.2–57.6 47.6 ± 6.5 34.8–60.5
FOLFIRI +
cetuximAb 78 (54) 36.4 ± 3.7 29.1–43.6 65.5 ± 3.6 58.5–72.5
* data for T stage, N stage, Vascular invasion, and grade missing in some cases due to being biopsy and/or liver metastases patients. OS and PFS analysis were conducted by omitting the missing data.
Cancers 2021, 13, 638 6 of 15
3. Results
3.1. Clinicopathological Features
The median patient follow-up time was 4 years, median OS was 28.5 months, and
median PFS was 19 months. All patients received FOLFIRI (irinotecan and modified de
Gramont), plus cetuximab or FOLFOX (oxaliplatin and modified de Gramont), plus cetux-
imab therapies as first line chemotherapy. Patients with G1 and G2 tumours were found to
have a better OS (p = 0.022), while patients treated with FOLFIRI plus cetuximab therapy
exhibited longer PFS (p = 0.007). A summary of patient clinicopathological characteristics
is shown in Table 1.
3.2. Immunohistochemical Expression of HER Family Members in Primary Tumours
For the first time in this study, we determined the expression of all four HER family
members as well as their co-expression, in tumours with wild type RAS from mCRC
patients before and after treatment, at different cut-off values and staining intensity, and
the results are presented in Table 2. The anti-EGFR mAb used in this study is specific for
the wild type EGFR, and does not cross react with the truncated EGFRvIII and, therefore,
detects only the level of ligand-dependent EGFR. For example, at cut off value of >5%, of
the 144 cases examined, 25%, 97%, 79%, and 48% were found to be positive for wtEGFR,
HER2, HER3, and HER4 respectively. wtEGFR and HER3 predominantly stained the
membrane, while HER2 exhibited cytoplasmic and HER4 nuclear staining patterns in the
majority of the cases (Figure 1, Table 2).
Table 2. Immunohistochemical expression of HER family members and their co-expressions in 144 mCRC patients treated
with anti-EGFR cetuximab.
Variables
No. of Positive Tumours (%)
% Positive Tumour Cells Intensity Location
>5 >10 >20 >50 1+ 2+ 3+ Mem Cyto Nuc
EGFR 36 28 17 8 26 15 2 31 14 -(25) (19) (12) (6) (18) (10) (1) (22) (10)
HER2 139 125 103 89 90 37 8 39 100 -(97) (87) (72) (62) (63) (26) (6) (27) (69)
HER3 114 79 55 29 67 38 10 70 43 -(79) (55) (38) (20) (47) (26) (7) (49) (30)
HER4 69 59 34 14 67 2 0 4 27 38(48) (41) (24) (10) (47) (1) (0) (3) (19) (26)
Co-expression of HER family (%)
EGFR EGFR EGFR HER2 HER2 HER3 EGFR EGFR EGFR HER2 EGFRHER2
HER2 HER3 HER4 HER3 HER4 HER4 HER2HER3 HER2HER4 HER3HER4 HER3HER4 HER3HER4
34 29 17 109 68 57 27 15 18 56 15
(24) (20) (12) (76) (47) (40) (19) (10) (13) (39) (10)
Mem, Membranous; Cyto, Cytoplasmic; Nuc, Nuclear.
The EGFR, HER2, HER3 staining intensity of 3+ were present in 1%, 6%, and 7% of
the cases examined respectively. None of the tumours had HER4 staining intensity of 3+
(Table 2, Figure 1).
The co-expression of the HER2 and HER3 was noted in the majority of the cases (76%),
while 10% co-expressed all four HER family members (Table 2). It is also noteworthy that,
in this study, we did not find the co-expression of HER family members to have a significant
statistical difference in both OS and PFS survival analyses (Supplementary Table S1).
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Figure 1. Immunostaining of Human Epidermal Growth Factor Receptor family members in mCRC
specimens. Immunostaining of wild type EGFR (wtEGFR) (A), HER2 (B), HER3 (C), and HER4 (D) in
formalin fixed paraffin embedded tumour sections stained immunohistochemically using the Ultra
Discovery Autostainer as described previously.
3.3. HER Expression in Primary CRC and Their Corresponding Metastases
Of the 21 patients with primary and paired metastasis (14 metachronous and 7 syn-
chronous metastases), 71% (15/21 patients) exhibited an overall change in one or more
HER expression (Table 3). Interestingly, in 38% (8/21) of cases, examined both the primary
tumour and related metastasis were EGFR negative (staining present in less than 5% of
tumour cells or staining intensity of 0) and 48% (10/21) patients had discordance in the
expression of wtEGFR in the primary tumours and related metastasis. Of these six EGFR
positive primary tumours, the corresponding metastatic sites were EGFR negative, whereas
in four EGFR positive metastasis, the primary tumours were EGFR negative (Table 3). Sim-
ilarly, there were 19%, 14%, and 52% discordance in the expression of HER2 (4/21), HER3
(3/21), and HER4 (11/21) in the primary tumours and related metastatic sites (Table 3).
3.4. wtEGFR Expression is Significantly Associated with Adverse Overall Survival
Using the wild type specific anti-EGFR mAb, the expression of EGFR and its as-
sociation with OS was investigated using Kaplan–Meier curves and log rank-test. We
found that OS was significantly poorer in patients with cytoplasmic expression of wtEGFR
(p = 0.003) in this study (Figure 2A). The expression of wtEGFR was an indicator of poorer
OS (hazard ratio (HR) 3.584, CI 1.455–8.826, p = 0.006) and remained an independent
prognostic biomarker of worse OS (p = 0.007) (Table 4). Interestingly, we also found the ex-
pression of wtEGFR at cut-off values of >20% and >50% to be significantly associated with
poorer OS (p = 0.008) (Figure 2A), and an independent biomarker for worse OS (HR 2.914,
CI 1.064–7.896, p = 0.038, HR 4.810, CI 1.320–17.524, p = 0.017 respectively) (Table 4).
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Table 3. Summary of HER expression in primary and corresponding metastatic lesions in CRC patients treated with anti-EGFR cetuximab.











1 Female 64 Metachronous −ve −ve −ve −ve +ve +ve −ve +ve Yes Yes
2 Female 52 Metachronous +ve −ve −ve −ve +ve −ve −ve +ve Yes Yes
3 Male 52 Synchronous −ve −ve −ve −ve +ve +ve +ve +ve No Yes
4 Male 60 Synchronous +ve +ve +ve −ve +ve +ve +ve −ve Yes No
5 Male 88 Metachronous +ve −ve −ve −ve +ve +ve +ve −ve Yes No
6 Male 61 Metachronous −ve −ve −ve −ve +ve +ve +ve −ve Yes Yes
7 Female 49 Synchronous −ve +ve −ve +ve +ve +ve +ve +ve Yes No
8 Female 69 Metachronous −ve −ve −ve −ve +ve +ve +ve +ve No No
9 Male 65 Metachronous −ve +ve −ve −ve +ve +ve +ve −ve Yes No
10 Female 50 Metachronous −ve −ve −ve −ve +ve +ve +ve +ve No No
11 Male 56 Metachronous +ve −ve −ve −ve +ve +ve +ve −ve Yes Yes
12 Male 70 Synchronous +ve +ve −ve −ve +ve +ve +ve +ve No Yes
13 Female 76 Metachronous −ve −ve −ve −ve +ve +ve +ve +ve No Yes
14 Male 62 Synchronous +ve −ve +ve −ve +ve +ve −ve +ve Yes Yes
15 Female 58 Metachronous −ve +ve −ve +ve +ve +ve −ve +ve Yes Yes
16 Male 65 Synchronous +ve +ve −ve −ve +ve +ve +ve +ve No Yes
17 Male 69 Metachronous +ve −ve −ve −ve +ve +ve +ve −ve Yes Yes
18 Male 74 Metachronous −ve −ve −ve −ve +ve +ve −ve +ve Yes Yes
19 Male 69 Metachronous +ve −ve −ve −ve −ve +ve +ve +ve Yes Yes
20 Male 35 Synchronous −ve −ve −ve −ve +ve −ve +ve +ve Yes No
21 Male 34 Metachronous −ve +ve −ve −ve +ve +ve +ve +ve Yes Yes
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Figure 2. The association between HER family members and OS in mCRC patients treated with cetuximab. Kaplan–Meier
survival curves showing the impact on the OS of the patients with localised cytoplasmic wtEGFR expression, wtEGFR
expression at >50% cut-off value, and HER4 expression at >20% cut off value (A), and impact on the PFS of patients with
localised membranous and cytoplasmic HER2 expression, HER3 3+ staining intensity (B). A log-rank test value of p ≤ 0.05
was considered statistical significance.
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Table 4. Univariate and multivariate analysis related to PFS and OS in 144 mCRC treated with anti-EGFR mAb cetuximab.
p-Value of ≤0.05 was considered significant.
Variables
Progression Free Survival (PFS)
Univariate Multivariate
HR 95% CI p-Value HR 95% CI p-Value
HER2 (Membranous) 2.097 1.242–3.542 0.006 2.560 1.295–5.059 0.007
HER2 (Cytoplasmic) 0.518 0.305–0.879 0.015 0.367 0.185–0.728 0.004
HER3 (3+) 2.307 0.986–5.398 0.054 - - NS
Overall Survival (OS)
Univariate Multivariate
HR 95% CI p-Value HR 95% CI p-Value
wtEGFR (Cytoplasmic) 3.584 1.455–8.826 0.006 3.822 1.446–10.103 0.007
wtEGFR (>20%) 3.084 1.274–7.464 0.013 2.914 1.064–7.986 0.038
wtEGFR (>50%) 4.473 1.309–15.287 0.017 4.810 1.320–17.524 0.017
HER2 0.213 0.62–0.734 0.014 - - NS
HR, hazard ratio; CI, confidence interval; NS, Not significant.
3.5. HER2 and HER3 Expression Impacts Progression Free Survival
A significant association was found between the HER2 expression and progression
free survival (Figure 2B). Interestingly, the membranous expression of HER2 was associated
with a shorter progression free survival (p = 0.004), while the cytoplasmic expression of
HER2 was found to be predictive of a better PFS (p = 0.012) (Figure 2B).
Univariate analysis further showed that HER2 membranous expression increased the
risk of shorter PFS by 2-fold (HR 2.097, CI 1.242–3.542, p = 0.006). It also remained an
independent predictive biomarker of shorter PFS when analysed in a multivariate model
(p = 0.007). Equally, cytoplasmic HER2 remained an independent predictive biomarker of
better PFS when analysed in univariate (HR 0.518, CI 0.305–0.879, p = 0.015) and multivari-
ate (p = 0.004) regression models (Table 4).
As shown in Table 2, HER3 was the second most commonly expressed receptor in this
study. Using Kaplan–Meier survival curves we found HER3 expression with a score of 3+
intensity to be significantly associated with shorter PFS (Figure 2, p = 0.045). While this
association was found to be significant, when analysed in the univariate and multivariate
cox-survival regression model, it did not reach significance to be an independent biomarker
of PFS when analysed (Table 4).
4. Discussion
The approval of the anti-EGFR mAbs—cetuximab and panitumumab—for the treat-
ment of mCRC and, in recent years, necitumumab for lung cancer [5,7,27–29], emphasises
the importance of EGFR as a therapeutic target in human cancers. Despite a response of
short duration in patients with mCRC, the inclusion of anti-EGFR therapy to chemotherapy
with FOLFOX or FOLFIRI has been shown to increase response rates and convert patients
with inoperable liver disease to potentially resectable metastatic disease [30]. However,
owing to various reasons, such as difference in the scoring criteria, there are no clear associ-
ations between the expression of EGFR protein and response to therapy [4]. Therefore, it
is currently recommended that patient selection should be based on the wild type (WT)
molecular status of RAS mutations rather than any expression of the EGFR protein, which
is the actual target for anti-EGFR antibodies [15,31].
Indeed, a well-characterized negative predictor of response to antibody therapy in
mCRC is mutated RAS [32]. However, objective response rates in patients with mutated
KRAS have been observed in several studies, while others have reported response rates of
up to 40% only in patients without mutations in KRAS or BRAF [18]. In addition, others
have reported emergence of KRAS mutations in liver metastases not detectable in the
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colonic biopsy, highlighting the role of intra-tumour heterogeneity as a major contributing
factor for intrinsic and/or acquired resistance [19].
Therefore, it is evident that it is vitally important to identify a more reliable predictive
biomarker of response to anti-EGFR therapy and/or more robust therapeutic targets
for monoclonal antibody or small molecule tyrosine kinase inhibitor-based therapy in
CRC [3,4]. Consequently, in the present study we aimed to investigate the predictive value
of the wtEGFR by determining its expression level, before and after anti-EGFR therapy
in patients with mCRC. In addition, for the first time, in this study we determined the
expression level of all other HER family members (HER2, HER3, and HER4), which act
as EGFR heterodimerisation partners, in mCRC patients with wild type RAS treated with
standard chemotherapy in combination with cetuximab.
In the present study, we report the immunohistochemical expression of the receptors
using various cut-off values for the percentage of staining as well as the location and
intensity of the immunostaining to maintain consistency with our previous studies [33]
(Table 2). We found the overall expression of wtEGFR to be a negative prognostic marker
of overall survival as both cytoplasmic expression of wtEGFR as well as positivity at more
than 50% cut-off value were found to be significantly associated with a shorter overall
survival in this study. Due to the fact that the anti-EGFR mAb cetuximab is incapable
of binding to the cytoplasmic wtEGFR, to induce the antibody-dependent cell-mediated
cytotoxicity (ADCC), this association was largely expected [34].
Interestingly, while the predominant pattern of the EGFR staining was membranous,
these findings are in contrast with our previous study in which the expression of the EGFR
was mostly present in the cytoplasm where we found a positive relationship between this
expression and response to treatment with cetuximab [26]. A possible explanation for
this discordance could be due to the fact that the present study included a significantly
larger proportion of patient tumours that were naïve to cetuximab treatment when the
EGFR expression was determined. Indeed, it is a well-investigated mechanism of action of
cetuximab, following binding with the EGFR, to downregulate the receptor by inducing
receptor internalisation [35–37]. Interestingly, while overexpression of membranous EGFR
is of great importance for targeted therapy with antibodies, in this study the EGFR staining
intensity of 3+ was only present in 1% of the cases examined (Table 3).
The abundant expression of HER2 (97%) and its significance as a predictive biomarker
of PFS, was an interesting and important observation of the present study. We found
the membranous expression of HER2 to be significantly associated with a shorter PFS,
while the opposite was found to be true for the cytoplasmic expression of HER2 in this
study. Several studies have examined the prognostic role of HER2 expression in colorectal
cancer [38–42], but very few have investigated the relative expression and predictive value
of HER2 and other HER family receptors in mCRC. We found a high expression of HER3
to be associated with a shorter PFS in this study and 26% and 7% of the cases examined
had staining intensity of 2+ and 3+, respectively (Table 3). These findings support the need
for more detailed investigation of HER2 and HER3, which can form heterodimers with
the EGFR, as predictive biomarkers for the response to therapy and therapeutic targets for
treatment with anti-EGFR antibodies and other forms of HER inhibitors, when used alone
and or in combinations in mCRC [37,43].
HER2 is known to preferentially dimerise with HER3, to initiate downstream sig-
nalling pathways for cell proliferation as well as angiogenesis [44]; therefore, both HER2
and HER3 receptors could represent effective therapeutic targets. Indeed, these receptors
are not only targeted for by mAb therapy, such as anti-HER2 antibody trastuzumab, which
has already been approved for metastatic gastric cancer and breast cancer, anti-HER3
antibody MM-121 and Pan-HER, an antibody mixture targeting EGFR, HER2, and HER3,
which is in early clinical development, but also using small molecule tyrosine kinase
inhibitors, such as lapatinib, and pan-HER blockers, such as afatinib, in various patient
populations, including CRC patients [43,45–47]. Interestingly, in a recent phase II, multi-
centre, open-label study treatment with trastuzumab conjugated with deruxtecan (T-DXd)
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have shown remarkable activity in patients with HER2-expressing mCRC refractory to
standard therapies [48]. In our study, we found that 10% of cases had HER2 staining
present in >10% tumour cells and 6% with staining intensity of 3+. These observations,
along with the strong associations between HER2 and HER3 expressions and PFS found
in the present study, provide further support that HER2 and HER3 measurements in tu-
mours from mCRC patients may be useful as predictive biomarkers for the response to
therapy. Furthermore, these measurements may provide vital information to determine ad-
ditional targets for therapeutic interventions in patients with colorectal cancer and warrant
further investigation.
Unlike the other HER family members, there are very few studies that have inves-
tigated the role of HER4 in human cancers, in particular mCRC [20,21,49,50]. To our
knowledge, this is the first study to report a significant number of mCRC patients treated
with cetuximab expressing HER4. While we did not find any significant association be-
tween HER4 expression and OS or PFS in this study, others have reported HER4 as an
independent prognostic factor. Biaocchi and colleagues investigated the expression of
HER4 in 109 CRC patients with high-risk of recurrence after radical surgery and found
positive membranous expression of HER4 to be an independent prognostic factor for
recurrence [20]. In a more recent study, HER4 expression was found to promote the pro-
gression of colorectal cancer through epithelial-mesenchymal transition and was related
to an unfavourable clinical outcome in patients with CRC [51]. Despite the membranous
cellular localisation of HER4 in our study, which was around 3%, we found overall 48% of
the cases were HER4 positive. The relatively common expression of HER4 in the present
study, which can act as an EGFR heterodimerisation partner, supports the need for further
investigation of its predictive value for the response to therapy with anti-EGFR mAbs in pa-
tients with mCRC. Currently, there are a number of ongoing clinical trials further assessing
the efficacy of HER family inhibitors in mCRC (EudraCT Number: 2020-000540-60, 2012-
002128-33, 2017-003466-28, 2020-001574-29, 2013-002872-42, 2014-003277-42; NCT03043313,
NCT03457896, NCT04603287).
Finally, in our study we found an overall response rate of 65% to chemotherapy plus
cetuximab in patients with wild type RAS status, which means that 35% of the patients
with no detectable mutations on RAS/RAF still exhibit an intrinsic resistance to therapy.
In our view, one of the biggest issues is the fact that often a small colorectal biopsy is
used for the single assessment of the patient’s cancer RAS status, which can often pre-date
the metastases significantly. Indeed, as shown by Baretti and colleagues, the reported
emergence of KRAS mutations in liver metastases may occur after anti-EGFR treatment
and not be detectable in the colonic biopsy [19]; however, more relevant, is the expression
level of the therapeutic target, which is often overlooked and/or not determined prior
to commencement of the treatment. Interestingly, we have shown that up to 71% of the
primary and paired metastasis exhibited an overall change in one or more HER expression
in this study. Similarly, other studies reported that EGFR expression was lost in 33% of
metastasising primary colorectal cancer tumours [23].
5. Conclusions
Taken together, we believe that for targeted therapy of cancer, the expression level of
the target antigen, and its status must not be overlooked, and it is time to get back to the
target, which in the case anti-EGFR antibodies are the EGFR protein and its dimerisation
partners [52–54]. We, therefore, recommend the need for more detailed examination of
both the primary tumours and corresponding metastasis to accurately determine the level,
cellular location, and intensity of the therapeutic target, which is the EGFR protein as well
as RAS status, when considering the use of EGFR targeted therapies in mCRC. Furthermore,
such studies may also help in the identification of those patients who may gain additional
benefit from the targeted therapy with the other forms of HER inhibitors.
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